
TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study
Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind usin...





